Background The management of MS is becoming increasingly complex with new DMTs reducing frequency and severity of relapses and accumulation of lesions[1].

Slides:

Advertisements

Similar presentations

Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,

Advertisements

What Is Meant by "Real-World Data?"

Do Health Care Regulation and Physician-Industry Interaction Influence Antibiotic Resistance Rates? The Example of Antimicrobial Prescribing and Dispensing.

1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.

1 The Budget Impact of Drugs Treating Rare Diseases in Canada: A MIDAS Sales Data Analysis April 14, 2015 Oral Presentation at the 2015 CADTH.

© Henley Business School 2008 Dr. Giampiero Favato Henley Business School University of Reading SEFAP University of Milan Long term sustainability of SSN.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.

FREEDOMS II TRIAL.

Fingolimod Therapy for Multiple Sclerosis

Cost-effectiveness of converting non- sedating antihistamines from prescription to over-the-counter status Michael B. Nichol, Ph.D. Patrick Sullivan, Ph.D.

Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology A 51-year-old woman with triplegia and blindness.

Medicines Differentiation Analysis Multiple Sclerosis 18 January 2011 Mary Perkins Expected Launch Date: 3/31/2013.

1 PhRMA Guiding Principles - DTC About Prescription Medicines.

A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis Timothy L. Vollmer, MD Professor, Neurology and Neuroscience.

ERS Cost of Foodborne Illness Data Product Sandra Hoffmann (ERS) Bryan Maculloch (FSIS)

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.

Practical Antibiotic Prescribing & Antibiotic Awareness Berny Baretto (Antibiotic Pharmacist) 21st November 2013.

Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.

Background Objectives Results Methods Within State Geographic Variation in Antipsychotic Medication Treatment for Medicaid-insured Children and Adolescents.

THE ENCLOSED SLIDES ARE FREE FOR PUBLIC USE DECEMBER 2015 ACHP Drug Cost Chart Pack.

Racial/Ethnic Differences in Pediatric Antipsychotic Use by FDA Labeled/Off-label Status MARYLAND CENTER FOR EXCELLENCE IN REGULATORY SCIENCE & INNOVATION.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.

Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.

Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Colorado.

THE ENCLOSED SLIDES ARE FREE FOR PUBLIC USE DECEMBER 2015 ACHP Drug Cost Chart Pack.

Impact of Currency Crisis on Availability, Affordability, and Use of Medicines in Indonesia: A 5-Year Longitudinal Study Sri Suryawati Center for Clinical.

Treating Mild Asthma: what’s in it for the patient? Regien Kievits,

Multiple Scleroris Lyle Wiemerslage, PhD.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Community Hospital Pharmacy Practice January 29, 2004

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis.

Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN

Propensity Score Adjustment for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie M. Hersh, DO,1 Claire Hara-Cleaver,

Response to chemotherapy

Cost per Course of Drug Therapy

Lecture 1 Introduction Kanar Fadhil Hidayat MSc. Pharmacy

Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018

Kandeke C, Chibuta C, Banda D

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

2011 Multiple Sclerosis Curriculum Overall Metrics

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.

MULTIPLE SCLEROSIS INCIDENCE IN TUSCANY FROM ADMINISTRATIVE DATA

Health Strategies Group

Clinical Cannabis Interprofessional Education: Program Development and Provider Knowledge Cameron, M.H. 1,2 & Jones, K.D.3,4 1. VA Portland Health Care.

Division of Viral Hepatitis, CDC

Chart 1.10: Total Prescription Drug Spending, 1980 – 2014(1)

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Clinical Pearls on Hot Topics in MS

Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.

Figure 1 Effect of DMF therapy on T cell subsets

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.

Pregnancy in MS.

Figure 2 Forest plots for subgroup analyses

Lecture 1 Introduction Kanar Fadhil Hidayat MSc. Pharmacy

Oral Therapies in MS.

Evaluation of the Use and Knowledge of Unlicensed Medication

MULTIPLE SCLEROSIS INCIDENCE IN TUSCANY FROM ADMINISTRATIVE DATA

Figure 2 Overall community differences in the gut microbiota of treated or untreated patients with MS Overall community differences in the gut microbiota.

Figure 1. Antibodies to MOG in a proportion of adult patients with MS

Figure 3 Multiple sclerosis (MS) immunomodulatory treatments interferon-β (IFNB) and fingolimod (FTY720) result in global perturbation of the immune system.

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.

Presentation transcript:

Background The management of MS is becoming increasingly complex with new DMTs reducing frequency and severity of relapses and accumulation of lesions[1]. Newly introduced oral therapies include dimethyl fumarate and fingolimod. Rituximab, has been used recently to treat MS, although off label[2]. Regardless of the increase in options, cost of MS DMTs has increased dramatically. Objectives To investigate pricing trajectories of MS DMTs, specifically glatiramer acetate(GA), rituximab(RTX), natalizumab(NTZ), fingolimod(FTY), and dimethyl fumarate (DMF) between To compare Anticipated vs. Market price of MS DMTs between , following the introduction of first oral DMT, FTY. Methods Data source: Market Price obtained from REDBOOK® for every year following approval of DMT. Assumption: Baseline Market and Anticipated Price is set at earliest 2010 Market Price for the DMT. Focus of analysis is comparing Market vs. Anticipated Price/Rate from baseline. Market Price: Average Wholesale Price (AWP) as conservative estimate with 15% discount rate. Anticipated Price: Expected Price based on Consumer Price Index (CPI) for Prescription Drugs with inflation adjusted is calculated using below equation: where r is the monthly CPI inflation rate for prescription drugs. Results Rate of costs for MS DMTs is substantially greater than the CPI rates of inflation for prescription drugs. There is a critical need to address these dramatically increasing MS DMT prices. Prescribers should be aware of the high price of MS DMTs, particularly the newly developed ones, and assess the cost-effectiveness of MS DMTs to provide patients with the most cost-effective option. Comparing the increase in cost of drug prices among Multiple Sclerosis drugs: Anticipated vs. Market Prices between Comparing the increase in cost of drug prices among Multiple Sclerosis drugs: Anticipated vs. Market Prices between Kim C.H. 1, Brandi Vollmer 2,3, Jon Campbell 1, John Corboy MD 2, Timothy Vollmer MD 2, Kavita V. Nair 1 1 Department of Clinical Pharmacy (DOCP), University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences 2 Rocky Mountain MS Center at CU, University of Colorado Department of Neurology 3 Colorado School of Public Health, University of Colorado Anschutz Medical Campus Key lesson: Prices of MS DMTs have increased drastically (at least 5% per year) with Market price increasing at a rate of at least 1.67 to 4.81 times compared to Anticipated price of MS DMTs. Conclusions References 1. Hart FM, Bainbridge J: Current and emerging treatment of multiple sclerosis. Am J Manag Care 2016, 22(6 Suppl):s Rommer PS, Dorner T, Freivogel K, Haas J, Kieseier BC, Kumpfel T, Paul F, Proft F, Schulze- Koops H, Schmidt E et al: Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). J Neuroimmune Pharmacol 2016, 11(1):1-8. Average Price Rate of Change per year for GA was 17.13% and 3.56% based on the Market and CPI inflation rate, respectively. The rate ratio indicated 4.81 times greater change in market price for GA compared to CPI inflation rate. Average Price Rate of Change per year for Rituximab was 6.68% and 4.01%, which was the lowest of all DMTs compared from Only 1.67 times greater change in Market price for Rituximab compared to CPI inflation rate. DMF had the highest market price increase per year with $6,614 while Rituximab showed the smallest increase of $1,510 from 2010 to * Market and Anticipated Rate differs based on different starting/ending price date.